Appointment of new team members
![](https://tracker.live.rns-distribution.com/track.live-rns/5198352_d9353a075fe0b610698e373da828b7e4.png)
28 May 2024
LEI: 213800RG7JNX7K8F7525
Life Science REIT plc
("Life Science REIT" or the "Company")
Investment Adviser appointments
Appointment of new team members
Life Science REIT (LSE: LABS), the real estate investment trust focused on UK life sciences properties, is pleased to announce two new appointments to Ironstone Asset Management, the Company's Investment Adviser.
Alex Wilshaw has joined as Associate Director - Asset Management following five years as an asset manager at Tilstone Partners, the Investment Adviser to Warehouse REIT. Alex specialises in asset management and investment projects and will apply these skills to drive key initiatives across the portfolio.
Alex Lowdell, an experienced leasing specialist with particular expertise in life sciences, has joined as Associate Director - Leasing. Alex spent nine years at DTRE in the Office, Science and Technology leasing team, focused on the Golden Triangle of Oxford, Cambridge and London's Knowledge Quarter.
With over 140,000 sq ft of life science space completed at Oxford Technology Park ("OTP") since 1 January 2023 or repurposed elsewhere on the portfolio, these appointments significantly strengthen the team as the Company moves to the next phase of its development and further accelerates leasing activity.
Simon Farnsworth, Managing Director of Ironstone Asset Management, the Company's Investment Adviser, said: "These appointments come at a very exciting time. We have made great progress at OTP and have recently commenced the repurposing of fully fitted lab space at Cambourne which marks a major step forward for that project. Investing in our team will further accelerate the strong progress already made in leasing activity and the many asset management initiatives underway."
END
Enquiries:
Ironstone Asset Management - Investment Adviser | +44 20 3011 2160 |
Simon Farnsworth, Managing Director | |
Joanna Waddingham, Head of Investor Relations and Corporate Affairs | |
|
|
Link Company Matters Limited - Company Secretary |
|
| |
|
|
Panmure Gordon (UK) Limited - Joint Corporate Broker | +44 20 7886 2500 |
Alex Collins / Tom Scrivens | |
|
|
Jefferies International Limited - Joint Corporate Broker | +44 20 7029 8000 |
Tom Yeadon / Oliver Nott
|
|
G10 Capital Limited - AIFM | +44 20 7397 5450 |
Maria Baldwin | |
Buchanan - Financial PR |
+44 20 7466 5000 |
Mark Court / Henry Wilson / Verity Parker | |
Notes to editors
Life Science REIT plc is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the "Golden Triangle" of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter and its strategic vision is to become the property provider of choice for life science companies in the UK.
Life Science REIT is addressing the acute demand-supply imbalance for laboratory space in the "Golden Triangle", which is characterised by low vacancy rates and prime rental increases. The UK life science sector itself is underpinned by strong structural drivers, including an ageing population and a supportive regulatory environment as well as the growing interdependence with technology, which is expanding the life science spectrum, driving strong demand for laboratory space.
The Company's diverse portfolio of assets ranges from a 20-acre science park currently under development through to fully let buildings, with an important part of the Company's strategy being the conversion of existing properties to laboratory space.
The Company's investment policy is focused on capital growth whilst also providing a growing level of income.
Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.
Further information is available at https://lifesciencereit.co.uk. To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.